摘要
目的:评价健脾补肾法治疗慢性阻塞性肺疾病稳定期(脾肾气虚型)患者的临床疗效及对血清中细胞因子IL-6、PARC/CCL-18的影响。方法:收集符合纳入标准的68例慢性阻塞性肺疾病稳定期患者,两组均给予西医基础治疗。随机将68例患者分为治疗组(35例)和对照组(33例)。治疗组在西医基础治疗同时给予中药四君子汤和金匮肾气丸合方汤剂治疗,疗程4周;观察两组治疗前后中医症状积分、临床疗效,CAT评分及IL-6、PARC/CCL-18的变化。结果:治疗组患者中医症状积分、CAT评分改善优于对照组(P<0.05);治疗组患者血浆IL-6、PARC/CCL-18水平低于对照组(P<0.05)。结论:健脾补肾法治疗慢性阻塞性肺疾病稳定期(脾肾气虚型),能明显减轻患者中医临床症状,改善患者的生活质量。其治疗的机制之一可能是通过促进IL-6、PARC/CCL-18的下降进而改善气道炎症。
Objective： To evaluate the clinical efficacy of strengthening the spleen and invigorating the kidney therapy of stable COPD（ the type of spleen and kidney qi deficiency） and the influence on serum cytokines IL- 6 and chemokines PARC/CCL-18. Methods： 68 cases were randomly divided into two groups which were both treated with basic treatment. The patients of trial group took Sijunzi Decoction and Jinkui Shenqi Pill for 4 weeks. And then the rate of TCM symptom score,CAT score and plasma IL- 6,PARC/CCL- 18 level were observed after the treatment. Results： The symptom and CAT score of the trial group were superior to the control group＇s The patients＇ plasma PARC/CCL- 18 and IL- 6 levels of the trial group were lower than those of the control group. Conclusion： Herbs of strengthening the spleen and invigorating the kidney can reduce the patients＇ plasma PARC /CCL- 18 and IL- 6 levels and have a better effect to treat COPD patients. One of the mechanisms of may be reducing the level of IL- 6 and PARC/CCL- 18 so as to decline the airway inflammation.
出处
《辽宁中医杂志》
CAS
北大核心
2015年第10期1848-1850,共3页
Liaoning Journal of Traditional Chinese Medicine
基金
四川省科技厅支撑计划项目(2011sz0084)
